CROHN Un champignon identifi comme facteur cl de la maladie mBio
Certes le microbiote a déjà été de multiples fois mis en cause dans le développement de la maladie de Crohn une maladie intestinale inflammatoire...
View ArticleAbbVie Showcases Commitment to Research and Innovation in Dermatology at the...
NORTH CHICAGO Ill. Sept. 26 2016 PRNewswire &160;AbbVie NYSE ABBV a global biopharmaceutical company today announced that new data on HUMIRA&174; adalimumab and investigational medicine...
View ArticleFDA gives the green light to the first Humira biosimilar
Amgens Amjevita has been given the go ahead for all eligible indications of its reference product including moderatetosevere rheumatoid arthritis moderatetosevere polyarticular juvenile idiopathic...
View ArticleFDA Approves STELARAĆ ustekinumab For Treatment Of Adults With Moderately To...
HORSHAM Pa. Sept. 26 2016 PRNewswire &160;Janssen Biotech Inc. announced today that the U.S. Food and Drug Administration FDA has approved STELARA&174; ustekinumab for the treatment of...
View ArticleBRIEFJanssen Biotech says FDA approves STELARA ustekinumab
Janssen Biotech says FDA approves STELARA ustekinumabfor treatment of adults with moderately to severely activecrohn's diseaseSource text for Eikon Further company coverage
View ArticleFDA approves J&J's autoimmune drug Stelara for Crohn's disease
Reuters Johnson & Johnson said on Monday that the U.S. Food and Drug Administration approved the company's blockbuster psoriasis drug Stelara for use in adults with Crohn's disease.
View ArticleGastroenterologists seeking better outcomes than Humira and Remicade for...
In a market long dominated by AbbVie's Humira adalimumab and Janssen's Remicade infliximab practice
View ArticleFDA approves J&Js autoimmune drug Stelara for Crohns disease Daily Mail
Financial ExpressFDA approves J&38;J's autoimmune drug Stelara for Crohn's diseaseDaily MailSept 26 Reuters Johnson &38; Johnson said on Monday that the U.S. Food and Drug Administration...
View ArticleFDA Clears Ustekinumab Stelara for Crohn's Disease
In clinical trials most patients who responded to induction therapy with ustekinumab and continued treatment achieved remission of symptoms. FDA Approvals
View ArticleJanssens Stelara Receives FDA Approval for Treatment of Adults with Crohns...
PR Newswire Horsham Pa. September 26 2016 Janssen Biotech Inc. announced today that the U.S. Food and Drug Administration FDA has approved STELARAĆ ustekinumab for the treatment of moderately to...
View ArticleFDA Approves Janssen's Crohn's Disease Treatment
NewsFDA approves STELARAĆ ustekinumab for treatment of adults with moderately to severely active Crohn's disease.
View ArticleStelara Given the GoAhead for Crohn's
MedPage Today Effective in patients with and without prior antiTNF failure
View ArticleFDA approves Janssens Stelara to treat Crohns disease
David SalazarJanssen Biotech announced Monday that the Food and Drug Administration had approved its Stelara ustekinumab to treat moderately to severely active Crohn’s disease. read more
View ArticleNew Crohns Indication Puts Janssens Stelara On Equal Ground With AntiTNFs
J&Js Janssen Biotech subsidiary won FDA approval for the IL12IL23 inhibitor Stelara to treat Crohns disease giving it a secondline...&160;&160;
View ArticleGtreeBNT Aims To Validate Business Model Via Licensing Deals
2017 may be a milestone year for GtreeBNT as it progresses its late clinical stage pipeline in the US for...&160;&160;&160;&160;
View ArticleJohnson & Jonsons Stelara receives FDA approval
The drug is approved for use to treat the skin condition scaly plaque psoriasis and a type of arthritis associated with psoriasis. Crohn's disease is a chronic inflammatory condition in the...
View ArticleFungus identified as key factor in the development of Crohn's disease
Recent medical research has focused on links between the fungal composition of human microbiota and chronic inflammatory bowel disease. A research team in Cleveland USA has identified one specific...
View ArticleNektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New...
SAN FRANCISCO Sept. 27 2016 PRNewswire &160;Nektar Therapeutics Nasdaq NKTR announced that it will host a conference call to discuss today's announcement of the new clinical collaboration with...
View ArticleInterview Strategies For Bio Manufacturing Partnerships
Boehringer Ingelheims head of BioXcellence its contract manufacturing business talks to Scrip about best practice when forming a longterm relationship...&160;&160;&160;
View ArticleINFOGRAPHIC Heart Failure A Growing Market
Heart failure is currently one of the most common reasons for hospitalization amongst people over 65 years of age. Causes...&160;&160;&160;&
View Article